Tatsuo Masubuchi

Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Salivary Duct Carcinoma

Hideaki Takahashi, Yuichiro Tada, Takashi Saotome et al. · Journal of Clinical Oncology · 2018 · 246 citations

A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma

C. Fushimi, Yuichiro Tada, Hideaki Takahashi et al. · Annals of Oncology · 2017 · 211 citations · Full text

Whole-Genome Sequencing of Sake Yeast Saccharomyces cerevisiae Kyokai no. 7

Takeshi Akao, Isao Yashiro, Akira Hosoyama et al. · DNA Research · 2011 · 152 citations · Full text

Comparative Genomics, Genetics, Genomics +19

Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma

Tatsuo Masubuchi, Yuichiro Tada, Shin-ichiro Maruya et al. · International Journal of Clinical Oncology · 2014 · 114 citations

Androgen Receptor, Clinicopathological Significance, Endocrine-related Cancer +9

Multicentre, retrospective study of the efficacy and safety of nivolumab for recurrent and metastatic salivary gland carcinoma

Kazutomo Niwa, Daisuke Kawakita, Toshitaka Nagao et al. · Scientific Reports · 2020 · 56 citations · Full text